Pelthos Therapeutics Inc. (PTHS)

Pelthos Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on bringing innovative therapies to patients with unmet treatment needs. The company became public in 2025 through a merger with Channel Therapeutics, and its common stock trades on NYSE American under the ticker PTHS.

Its lead product is ZELSUVMI (berdazimer topical gel), a nitric oxide-releasing medication approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum, a common contagious viral skin infection that primarily affects children. ZELSUVMI is applied at home by patients or caregivers, offering an alternative to in-office procedures such as scraping or freezing lesions.

Pelthos markets the product to dermatologists and pediatricians in the United States and seeks to expand its portfolio by acquiring or licensing additional therapies, while continuing development programs inherited from Channel Therapeutics, including non-opioid pain treatments.